Artificial intelligence startup Viz.ai raised $100 million in its fourth round of funding and has reached a valuation of $1.2 billion, the company announced April 7.
Neurosurgeon Chris Mansi, MD, is co-founder and CEO of the company, which uses AI to accelerate care coordination and reduce "delays that stand between patients and life-saving treatments," according to the company's website.
The company's stroke triage software, Viz LVO, features an image analysis tool designed to facilitate fast and accurate triage of suspected large vessel occlusions in stroke patients.
"We will continue to invest heavily in cutting edge technology and services to integrate deeply into the clinical workflow, allowing us to automate disease detection, increase diagnostic rates and enhance workflows across the entire hub-and-spoke health system," Dr. Mansi said. "More patients receive the right treatment, resulting in better patient outcomes and improved financial efficiency for the health system."
More than 1,000 hospitals use the company's technology, which has reached millions of patients, according to Viz.ai. Over the past year, it has launched AI systems for aortic disease, pulmonary embolism and cerebral aneurysms, and received its first five CE Marks in 2021.
The company has grown from 180 employees to more than 350 over the past 12 months and plans to add almost 200 team members in the next year.
The recent funding round was led by Insight Partners, a private equity and venture capital firm, and Tiger Global, an investment firm.